Cordium Pharmaceuticals Pvt Ltd is a reliable Indian pharmaceutical exporter supplying Trastuzumab Biosimilar 150mg and 440mg Injection for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric cancer.
We support:
Government tenders
Private hospitals
Oncology centers
Cancer institutes
Retail & specialty pharmacies
Pharma distributors
International importers
Personal import programs (subject to local regulations)
The global demand for trastuzumab biosimilars is increasing because biosimilars improve accessibility and reduce treatment costs while maintaining comparable quality, safety and efficacy standards.
Product Information
Trastuzumab Biosimilar Injection
Strengths Available
Trastuzumab Biosimilar 150mg Injection
Trastuzumab Biosimilar 440mg Injection
Therapeutic Category
Oncology | Monoclonal Antibody | HER2 Targeted Therapy
Indications
Used for treatment of:
HER2 Positive Early Breast Cancer
HER2 Positive Metastatic Breast Cancer
HER2 Positive Metastatic Gastric Cancer
Trastuzumab is considered an essential oncology medicine by WHO and has significantly expanded access through biosimilar adoption globally.
Why Hospitals & Distributors Choose Cordium Pharmaceuticals Pvt Ltd
✅ WHO-GMP Manufacturing Partnerships
✅ Export Documentation Support
✅ Cold Chain Packaging Available
✅ International Shipping Coordination
✅ Competitive Bulk Pricing
✅ Tender Supply Support
✅ Regulatory Documentation Assistance
✅ Reliable Supply Chain Management
Countries We Export Trastuzumab Biosimilar To
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 USA
🇬🇧 UK
🇿🇦 South Africa
WHO notes that biosimilars can reduce treatment costs by around 60–65%, improving accessibility, particularly in low- and middle-income countries.
The global trastuzumab biosimilar market continues to expand due to increasing cancer prevalence, growing physician confidence and broader hospital adoption.
Regulatory Notice
Trastuzumab is a prescription-only oncology medicine.
Availability, importation, marketing authorization and personal import rules vary by country. Supply is subject to local health authority regulations and valid medical documentation where applicable.
Contact Cordium Pharmaceuticals Pvt Ltd
Global Export Division
Cordium Pharmaceuticals Pvt Ltd
Partner for:
Hospitals
Cancer Institutes
Specialty Pharmacies
Oncology Distributors
Government Procurement Agencies
International Importers
Request:
✔ Product Dossier
✔ COA
✔ Export Documentation
✔ Bulk Quotation
✔ Tender Participation Support
✔ International Shipping Assistance
We support:
Government tenders
Private hospitals
Oncology centers
Cancer institutes
Retail & specialty pharmacies
Pharma distributors
International importers
Personal import programs (subject to local regulations)
The global demand for trastuzumab biosimilars is increasing because biosimilars improve accessibility and reduce treatment costs while maintaining comparable quality, safety and efficacy standards.
Product Information
Trastuzumab Biosimilar Injection
Strengths Available
Trastuzumab Biosimilar 150mg Injection
Trastuzumab Biosimilar 440mg Injection
Therapeutic Category
Oncology | Monoclonal Antibody | HER2 Targeted Therapy
Indications
Used for treatment of:
HER2 Positive Early Breast Cancer
HER2 Positive Metastatic Breast Cancer
HER2 Positive Metastatic Gastric Cancer
Trastuzumab is considered an essential oncology medicine by WHO and has significantly expanded access through biosimilar adoption globally.
Why Hospitals & Distributors Choose Cordium Pharmaceuticals Pvt Ltd
✅ WHO-GMP Manufacturing Partnerships
✅ Export Documentation Support
✅ Cold Chain Packaging Available
✅ International Shipping Coordination
✅ Competitive Bulk Pricing
✅ Tender Supply Support
✅ Regulatory Documentation Assistance
✅ Reliable Supply Chain Management
Countries We Export Trastuzumab Biosimilar To
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 USA
🇬🇧 UK
🇿🇦 South Africa
WHO notes that biosimilars can reduce treatment costs by around 60–65%, improving accessibility, particularly in low- and middle-income countries.
The global trastuzumab biosimilar market continues to expand due to increasing cancer prevalence, growing physician confidence and broader hospital adoption.
Regulatory Notice
Trastuzumab is a prescription-only oncology medicine.
Availability, importation, marketing authorization and personal import rules vary by country. Supply is subject to local health authority regulations and valid medical documentation where applicable.
Contact Cordium Pharmaceuticals Pvt Ltd
Global Export Division
Cordium Pharmaceuticals Pvt Ltd
Partner for:
Hospitals
Cancer Institutes
Specialty Pharmacies
Oncology Distributors
Government Procurement Agencies
International Importers
Request:
✔ Product Dossier
✔ COA
✔ Export Documentation
✔ Bulk Quotation
✔ Tender Participation Support
✔ International Shipping Assistance
Keywords
